Role of rifaximin in the management of alcohol‐associated hepatitis: A systematic review and meta‐analysis

Alcohol‐associated hepatitis (AAH) is an acute, inflammatory liver disease with severe short‐term and long‐term morbidity and mortality. AAH can lead to severe complications including hepatic failure, gastrointestinal bleeding, sepsis, and the development or decompensation of cirrhosis. Rifaximin is an antibiotic that reduces bacterial overgrowth and gut translocation, and it may have a role in decreasing systemic inflammation and infection in patients with AAH. Therefore, we conducted a systematic review and meta‐analysis to evaluate the role of rifaximin in the management of AAH.

[1]  M. Shimizu,et al.  Effects of Rifaximin on Circulating Albumin Structures and Serum Ammonia Levels in Patients with Liver Cirrhosis: A Preliminary Study , 2022, Journal of clinical medicine.

[2]  V. Shah,et al.  Review article: current and emerging therapies for acute alcohol‐associated hepatitis , 2022, Alimentary pharmacology & therapeutics.

[3]  Maggie W Hansell,et al.  Alcoholic Hepatitis: Diagnosis and Management. , 2022, American family physician.

[4]  H. Møller,et al.  The impact of rifaximin on inflammation and metabolism in alcoholic hepatitis: A randomized clinical trial , 2022, PloS one.

[5]  R. Schwabe,et al.  Effect of rifaximin on infections, acute‐on‐chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA‐AH) , 2022, Liver international : official journal of the International Association for the Study of the Liver.

[6]  F. Nevens,et al.  Treatment of severe alcoholic hepatitis: A systematic review. , 2021, Current opinion in pharmacology.

[7]  N. Pyrsopoulos,et al.  Emerging Therapies for Alcoholic Hepatitis. , 2021, Clinics in liver disease.

[8]  T. Sandahl,et al.  No Effect in Alcoholic Hepatitis of Gut-Selective, Broad-Spectrum Antibiotics on Bacterial Translocation or Hepatic and Systemic Inflammation , 2021, Clinical and translational gastroenterology.

[9]  G. Szabo,et al.  Emerging medical therapies for severe alcoholic hepatitis , 2020, Clinical and molecular hepatology.

[10]  V. Shah,et al.  The knowns and unknowns of treatment for alcoholic hepatitis. , 2020, The lancet. Gastroenterology & hepatology.

[11]  D. Crabb,et al.  Diagnosis and Treatment of Alcohol‐Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases , 2020, Hepatology.

[12]  J. Veryan,et al.  Recent advances in alcoholic hepatitis , 2019, Frontline Gastroenterology.

[13]  S. Atkinson,et al.  The future of therapy for alcoholic hepatitis – Beyond corticosteroids , 2019, Journal of hepatology.

[14]  T. Karlsen,et al.  Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency , 2019, Scientific Reports.

[15]  John P. Rice,et al.  Outcomes of Early Liver Transplantation for Patients With Severe Alcoholic Hepatitis. , 2018, Gastroenterology.

[16]  R. Bataller,et al.  Clinical Guideline : Alcoholic Liver Disease , 2018 .

[17]  C. Stave,et al.  Systematic review with meta‐analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis , 2017, Alimentary pharmacology & therapeutics.

[18]  R. Bataller,et al.  Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: Prediction and impact on long‐term survival , 2017, Hepatology.

[19]  A. Duhamel,et al.  Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: A prospective study , 2017, Hepatology.

[20]  N. Lanthier,et al.  Treatment of severe alcoholic hepatitis: past, present and future , 2017, European journal of clinical investigation.

[21]  Ariel W. Aday,et al.  Alcoholic hepatitis: current trends in management , 2017, Current opinion in gastroenterology.

[22]  N. Pyrsopoulos,et al.  Emerging concepts in alcoholic hepatitis , 2017, World journal of hepatology.

[23]  S. Atkinson,et al.  In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA , 2017, Gastroenterology.

[24]  S. Sidhu,et al.  New paradigms in management of alcoholic hepatitis: a review , 2017, Hepatology International.

[25]  A. Gurakar,et al.  Current Management of Alcoholic Hepatitis and Future Therapies , 2016, Journal of clinical and translational hepatology.

[26]  M. Thursz,et al.  Treatment of Severe Alcoholic Hepatitis. , 2016, Gastroenterology.

[27]  Ramon Bataller,et al.  Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia. , 2016, Gastroenterology.

[28]  S. Friedman,et al.  Early Liver Transplantation for Severe Alcoholic Hepatitis in the United States—A Single‐Center Experience , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[29]  J. Cuthbert,et al.  Alcoholic Hepatitis: Risk Factors, Pathogenesis, and Approach to Treatment. , 2016, Alcoholism, clinical and experimental research.

[30]  J. Bajaj.  Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis , 2016, Alimentary pharmacology & therapeutics.

[31]  A. Dhanda,et al.  Immune dysfunction in acute alcoholic hepatitis. , 2015, World journal of gastroenterology.

[32]  R. Bataller,et al.  Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis , 2015, Hepatology.

[33]  Philip Wong,et al.  Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver , 2014, Hepatology.

[34]  S. Verma,et al.  Alcoholic hepatitis: diagnosis and management in 2012 , 2012, Expert review of gastroenterology & hepatology.

[35]  Y. Kuo,et al.  Hepatitis C virus infection in alcoholic hepatitis: prevalence patterns and impact on in-hospital mortality , 2012, European journal of gastroenterology & hepatology.

[36]  F. Pruvot,et al.  Early liver transplantation for severe alcoholic hepatitis. , 2011, The New England journal of medicine.

[37]  R. Soloway,et al.  Recent and currently emerging medical treatment options for the treatment of alcoholic hepatitis. , 2011, World journal of hepatology.

[38]  Cheng-Fu Xu,et al.  Early mortality of alcoholic hepatitis: a review of data from placebo-controlled clinical trials. , 2010, World journal of gastroenterology.

[39]  M. Thursz,et al.  Prednisolone or Pentoxifylline for Alcoholic Hepatitis. , 2015, The New England journal of medicine.